SCHEMBL1715784

SCHEMBL1715784

O=C(O)c1ccccc1NCC1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 3/20 0.52
KCNH3 Q9ULD8 1/20 0.50
LIPC P11150 1/20 0.49
LIPG Q9Y5X9 1/20 0.49
ALDH1A1 P00352 4/20 0.49
HPGD P15428 2/20 0.49
HSD17B10 Q99714 2/20 0.49
KDM4E B2RXH2 3/20 0.48
AGTR1 P30556 1/20 0.48
RAB9A P51151 1/20 0.48
CREBBP Q92793 1/20 0.46
POLB P06746 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CNR1 P21554 2/20 0.45
CNR2 P34972 2/20 0.45
FABP4 P15090 2/20 0.44
CLCN2 P51788 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
ASPH Q12797 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL194971 0.89 KDM4C (0.63) KDM4CLIPCLIPGALDH1A1HPGD
SCHEMBL11503155 0.85 KDM4C (0.66) KDM4CLIPCLIPGALDH1A1HPGD
SCHEMBL5861688 0.85 KDM4E (0.54) ALDH1A1HPGDHSD17B10KDM4EPOLB
SCHEMBL29668628 0.81 HPGD (0.50) KDM4CKCNH3ALDH1A1HPGDHSD17B10
SCHEMBL30002422 0.81 HPGD (0.50) KDM4CKCNH3ALDH1A1HPGDHSD17B10
SCHEMBL1715377 0.78 RXFP1 (0.47) KDM4CKCNH3ALDH1A1KDM4ECREBBP
SCHEMBL31391653 0.77 GRIK1 (0.49) ALDH1A1HPGDHSD17B10KDM4ERAB9A
SCHEMBL22029499 0.75 KDM4C (0.54) KDM4CLIPCLIPGALDH1A1HPGD
SCHEMBL28912678 0.75 KDM4C (0.54) KDM4CLIPCLIPGALDH1A1HPGD
SCHEMBL5793778 0.74 KCNH3 (0.65) KCNH3ALDH1A1KDM4ERAB9ACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US claimed
CN-1906155-A Novel hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA AS (DK) 2007-01-31 CN claimed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
CN-1906155-A Novel hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA AS (DK) 2007-01-31 CN disclosed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP disclosed
US-7012081-B2 Anthranyl amides and their use as medicaments SCHERING AG (DE) 2006-03-14 US disclosed
US-20050261343-A1 Anthranilamides and their use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-11-24 US disclosed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO disclosed
US-20040029880-A1 Anthranyl amides and their use as medicaments BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261343-A1 Anthranilamides and their use as pharmaceutical agents AADAC, ANTXR2, VEGFA KDM4C 3588/4885KCNH3 4498/4885LIPC 3632/4885
US-20040029880-A1 Anthranyl amides and their use as medicaments AADAC, ANTXR2, VEGFA KDM4C 3787/4885KCNH3 4536/4885LIPC 3763/4885
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 KDM4C 2109/4885KCNH3 4012/4885LIPC 2541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.